Year: 2024
Type: article
Abstract: In this issue of Blood, Yeung et al 1 report high molecular response rates and good tolerability of the first-in-class allosteric BCR::ABL1 inhibitor asciminib in a single-arm phase 2 study of 101 patients with newly diagnosed chronic phase chronic myeloid leukemia (CP-CML), thereby bolstering the case for asciminib as a first-line treatment option.Conflict-of-interest disclosure: N.P.
Source: Blood
Author: Neil P. Shah
Institution: University of California, San Francisco
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4404124024